T. Rowe Price Associates
ELVN icon

T. Rowe Price Associates’s Enliven Therapeutics ELVN Stock Holding History

T. Rowe Price Associates’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147M Buy
2,903,907
+2,806,160
+2,871% +$119M 0.01% 592
2026
Q1 		$3.83M Buy
97,747
+73,947
+311% +$2.05M ﹤0.01% 1530
2025
Q4 		$367K Sell
23,800
-207,504
-90% -$4.13M ﹤0.01% 2538
2025
Q3 		$4.74M Sell
231,304
-296,946
-56% -$5.99M ﹤0.01% 1409
2025
Q2 		$10.6M Buy
528,250
+512,090
+3,169% +$9.69M ﹤0.01% 1101
2025
Q1 		$319K Buy
16,160
+2,533
+19% +$54.5K ﹤0.01% 2440
2024
Q4 		$307K Buy
13,627
+1,980
+17% +$51.3K ﹤0.01% 2499
2024
Q3 		$298K Buy
11,647
+440
+4% +$10.2K ﹤0.01% 2480
2024
Q2 		$262K Buy
+11,207
New +$236K ﹤0.01% 2485

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

T. Rowe Price Associates's ELVN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Enliven Therapeutics (ELVN) stake by 2,871% in Q2 2026, buying an estimated $119M and bringing the position to 2,903,907 shares worth $147M. The position accounts for 0.01% of the portfolio, ranked #592.

T. Rowe Price Associates first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • T. Rowe Price Associates held 2,903,907 shares of Enliven Therapeutics worth $147M as of Q2 2026.
  • T. Rowe Price Associates bought 2,806,160 Enliven Therapeutics shares in Q2 2026, an estimated $119M.
  • Enliven Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #592 holding.
  • T. Rowe Price Associates first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.